Tas, CetinOzkan, Cansel KoseSavaser, AyhanOzkan, YalcinTasdemir, UmutAltunay, Hikmet2024-09-182024-09-1820060939-64111873-3441https://doi.org/10.1016/j.ejpb.2006.05.017https://hdl.handle.net/20.500.12483/113124th International Postgraduate Research Symposium on Pharmaceutics (IPORSHIP-2004) -- SEP 20-22, 2004 -- Istanbul, TURKEYThere is a need for nasal drug delivery of metoclopramide HCI (MTC) in specific patient populations where the use of commercially available intravenous and oral dosage forms may be inconvenient and/or unfeasible. In this perspective, nasal dosage forms (solution, gel and lyophilized powder) of MTC were prepared by using a mucoadhesive polymer Carbopol 981 (CRB 981). The drug release studies of formulations were performed by using a modified horizontal diffusion chamber with cellulose membrane and excised cattle nasal mucosa as diffusion barriers. After the ex vivo experiments, the morphological appearances of the nasal mucosa were analyzed with the light microscopic studies. In vivo experiments were carried on sheep model. The release of MTC from solution and powder formulations was found higher than gel formulation (p < 0.05) and no severe damage was found on the integrity of nasal mucosa after ex vivo experiments. The penetration enhancing effect of dimethyl-p-cyclodextrin (DM-beta-CD) used in powder formulations was observed in ex vivo and in vivo experiments. In contrast to in vitro and ex vivo experiments the nasal bioavailability of gel formulation was found higher than those of the solution and powder (p < 0.05) and might represent a promising novel tool for the systemic delivery of MTC. (c) 2006 Elsevier B.V. All rights reserved.eninfo:eu-repo/semantics/closedAccessnasal drug deliverymetoclopramidecarbopol 981sheeppowderDM-beta-CDConference Object64224625410.1016/j.ejpb.2006.05.017168704092-s2.0-33748197020Q1WOS:000240726800017Q2